Information  X 
Enter a valid email address

Kanabo Group PLC (KNB)


Friday 25 June, 2021

Kanabo Group PLC

Initial Commercial Scale Production

RNS Number : 0752D
Kanabo Group PLC
25 June 2021

25 June 2021

Kanabo Group Plc

("Kanabo" or "the Company")


Initial Commercial Scale Production



Kanabo Group Plc (LSE:KNB), London-based medical cannabis R&D company, announces that the Company, in partnership with Pure Origin Group, has completed its first EU-GMP production line. This production marks the end of the Company's pilot sales and preludes a full product launch within Kanabo's primary markets, with the company embarking on the second phase of its sales plan to increase revenue from the sale of CBD products.

As previously announced on 20 May 2021, Pure Origin created a dedicated production line for Kanabo's CBD Wellness formulas using Kanabo's equipment, production protocols and IP. The company was chosen specifically for its Good Manufacturing Practices (GMPs) to regulate production, verification and validation, ensuring that Kanabo's finished products are effective and safe for market distribution.

Kanabo CEO, Avihu Tamir, said:

"In one month we have succeeded in a joint effort with the Pure Origin team to establish a EU-GMP production line for Kanabo's medical grade Hemp CBD line. This production is a key achievement that will bring a new quality of medical CBD vape products that were not previously available on to the UK market."

Pure Origin Joint Managing Director, Tony Rolfe, added :

"We are delighted to partner with Kanabo in the run up to full production and product launch of their EU-GMP manufactured CBD formulas."


For further information, please visit or contact the following:

Kanabo Group Plc

Tel: +(972)52-3173-633

[email protected]

Meirav Horn


Peterhouse Capital Limited (Financial Adviser)

Tel: +44 (0)20 7469 0930

Eran Zucker / Guy Miller / Allie Feuerlein


Peterhouse Capital Limited (Corporate Broker)

Lucy Williams / Charles Goodfellow



Kanabo aims to be an industry leader in product development and commercialisation of both cannabis-derived products for medical patients and THC-free products for CBD consumers. The company develops high-quality medical cannabis extract formulas, medical device vaporisers, and other innovative delivery methods. Validation activities are conducted at Kanabo's research lab at the Weizmann Science Park in Israel. With a primary focus on the German and UK Markets, Kanabo has already begun penetrating the European Market, and is positioned to scale up to meet growing market demand and projected sales. Currently, Kanabo is selling its line of CBD formulas for inhalation in the UK and Germany and has agreements with top distributors in the pharmaceutical and OTC sectors already in place.



Pure Origin Group has been providing Pharma EU GMP contract manufacturing solutions at a facility in Wales for over 20 years (under different trading names). The company has amassed an extensive range of experience working with global brands in the pharmaceutical, cosmetic, food and nicotine industries across several product categories. The company's outstanding GMP disciplines and processes enable the ability to offer Customers all aspects of CBD manufacturing, from the processing and manufacturing of CBD extracts, to the ongoing development of new products (oils/tinctures, e-liquids, vaping pod systems, topicals / cosmetics, balms, soft gel capsules etc.), all underpinned by unrivalled product stewardship and testing.


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t